Skip To Main Content
This website is intended exclusively for healthcare professionals residing and/or working in Oman.
Campus
Campus

Blood Eosinophils: A Biomarker in COPD

blood-eosinophils-slide-1
blood-eosinophils-slide-2

 

aCOPDGene study (n=1553). Risk estimates derived from negative binomial regression models adjusted for age, sex, race, previous exacerbations, gastroesophageal reflux, SGRQ score, post-BD FEV1 percentage predicted, and WBC count. bECLIPSE multicenter, multinational, 3-year longitudinal study; 1895 patients with GOLD spirometry grade 2 to 4 with complete CBC and 3-year follow-up data were analyzed. cPatients with clinical COPD: smoking history ≥10 pack-years, FEV1 ≤70% predicted, and ≥1 moderate or severe exacerbation in previous year. Copenhagen general population study (n=203). Exacerbation risk date shown here are Incidence Rate Ratio. A severe exacerbation was defined as a hospitalization due to COPD.

COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; EOS, eosinophils; ICS, Inhaled corticosteroids; CBC, Complete Blood Count; ULN, Upper Limit of Normal.

All reported risk estimates are significantly different from reference (<100 cells/uL).

  1. Bélanger M, et al. Int J Chron Obstruct Pulmon Dis. 2018;13:3045–3054.
  2. Halpin DMG, et al. EClinicalMedicine. 2019;14:32–41.
  3. Casanova C, et al. Eur Respir J. 2017;50:1701162.
  4. Yun JH, et al. J Allergy Clin Immunol. 2018;141:2037–2047.
  5. Oshagbemi OA, et al. COPD. 2019;16:152–159.
  6. Oshagbemi OA, et al. Am J Respir Crit Care Med. 2017;195:1402–1404.
  7.  Ajithkumar CS. Ind J Basic Appl Med Res. 2018;7:223–228.
  8. Wu HX, et al. Front Med (Lausanne). 2019;6:282.
  9. Singh D, et al. Eur Respir J. 2014;44:1697–1700.
  10. Bafadhel M, et al. Am J Respir Crit Care Med. 2011;184:662–671.
  11. Leigh R, et al. Eur Respir J. 2006;27:964–971.
  12. Vedel-Krogh S, et al. Am J Respir Crit Care Med. 2016;193:965–974.
  13. Müllerova H, et al. Int J Chron Obstruct Pulmon Dis. 2019;14:683–696.
  14. Tan et al. Eur Respir J 2021;57(5):2000838.
  15. Beech A, et al. Biomedicines. 2022;10(10):2611.
  16. Southworth T, et al. Eur Respir J. 2018;52(1):1800427.
  17. Ellingsen J, et al. ERJ Open Res. 2021;7(4):00471-2021.
  18. Pongdee T, et al. J Allergy Clin Immunol Glob. 2022;1(4):233-240.
  19. Benson VS, et al. Eur Respir J. 2022;59(1):2004590.
  20. Kreindler JL, et al. BMJ Open Respir Res. 2016;3(1):e000151.
  21. Chipps BE, et al. Ann Am Thorac Soc. 2021;18(12):1978-1987.
  22. Fujimoto K, et al. Eur Respir J. 2005;25(4):640-646.
Related articles
Every Exacerbation Counts
  • Chronic Obstructive Pulmonary Disease

Every Exacerbation Counts

Read article
Lung Function in COPD
  • Chronic Obstructive Pulmonary Disease

Lung Function in COPD

Read article
Dupilumab Efficacy Across Baseline Eosinophil Counts in COPD
  • Chronic Obstructive Pulmonary Disease

Dupilumab Efficacy Across Baseline Eosinophil Counts in COPD

Dupilumab Efficacy in COPD Patients with Type 2 Inflammation: Post Hoc Analysis Stratified by Baseline
Blood Eosinophil Counts (≥150 vs ≥300 cells/μL) from Pooled BOREAS and NOTUS Data

Read article
MAT-BH-2600506-1.0-09/2026